Drugs / Recombinant COVID-19 vaccine (Sf9 cells)
Recombinant COVID-19 vaccine (Sf9 cells)
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05013983 | Jul → Dec 2024 | COVID-19 | WestVac Biopharma Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04718467 | Feb → May 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Withdrawn | No outcome recorded |
| Phase 2 | NCT04640402 | Nov 2020 → Feb 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04904471 | Jun 2021 → Jan 2022 | COVID-19 | WestVac Biopharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant COVID-19 vaccine (Sf9 cells) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04904471 ↗ |
| Known as | Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells) | “A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)” NCT04640402 ↗ |
| Modality | Vaccine | “Recombinant COVID-19 vaccine (Sf9 cells)” NCT04718467 ↗ |